论文部分内容阅读
目的：研究９ ９ｍ Ｔｃ －ｓｅｓｔａｍｉｂｉ（ 甲氧基乙丁基异睛） ＭＤＲ１ Ｐ－ｇｐ 的检出率与疗效、预后的关系，及与免疫组化结果的相关性。方法：疗前、疗后检测９９ ｍ Ｔｃ－ｓｅｓｔａｍｉｂｉ 的滞留值判断肿瘤细胞Ｐ－ ｇｐ 泵出功能。结果：全组检出率５０％ （５７／１１５） ，肺癌５１％ （５５／１０８） ，肺转移癌２９％ （２／７）。ＮＳＣＬＣ与ＳＣＬＣ检出率无差别，但在９９ ｍ Ｔｃ－ｓｅｓｔａｍｉｂｉ 检出Ｐ－ ｇｐ（＋ ）中ＮＳＣＬＣ７８％ （４３／５５） ，明显高于ＳＣＬＣ２２％ （１２／５５） 。５９ 例疗前，疗后总符合率９０ ％（５３／５９）：阳性符合率４６ ％ ；阴性符合率４４％ 。疗前Ｐ－ ｇｐ（－ ） 、疗后Ｐ－ｇｐ（ ＋）１０％ 。Ｐ－ ｇｐ 特异性单抗Ｃ２１９ 免疫组化检测２５ 例肺癌标本，与９９ ｍ Ｔｃ－ ＭｉＢｉ 总符合率７２ ％（１８／２５），互补２８％ （７／２５） 。９９ｍ Ｔｃ － ＭｉＢｉ 示Ｐ－ ｇｐ（ －） 者ＣＲ＋ ＰＲ均明显优于Ｐ－ｇｐ（ ＋ ）者（ Ｐ＜ ０．０１） 。４１／５７ 例Ｐ－ ｇｐ（＋ ）者化疗期并用耐药调变剂，ＲＲ２４％ 。肺癌２８％（１＋ １０／３９） ：ＮＳＣＬＣ２１％（０＋ ６／２９） ；ＳＣＬＣ?
Objective: To investigate the relationship between the detection rate of 9 9m Tc-sestamibi MDR1 P-gp and its efficacy, prognosis, and correlation with immunohistochemical results. Methods: Pretreatment and post-treatment were used to determine the retention of 99 μg Tc-sestamibi to determine the P-gp function of tumor cells. Results: The overall detection rate was 50% (57/115), lung cancer 51% (55/108), and metastatic lung cancer 29% (2/7). There was no difference in the detection rate between NSCLC and SCLC, but NSCLC detected 78% (43/55) in 99 g Tc-sestamibi, which was significantly higher than that in SCLC (22/55). Before treatment, the total compliance rate after treatment was 90% (53/59): the positive rate was 46%; the negative rate was 44%. P-gp(-) before treatment and P-gp(+) 10% after treatment. P-gp-specific monoclonal antibody C219 immunohistochemistry detected 25 lung cancer specimens, and the total coincidence rate with 99m Tc-MiBi was 72% (18/25), complementary to 28% (7/25). 99m Tc - MiBi showed that CR + PR in P-gp (-) was significantly better than P-gp (+) (P < 0.01). 41/57 patients with P-gp(+) were treated with drug-resistance modulators during the chemotherapy period, RR24%. Lung cancer 28% (1+10/39): NSCLC21% (0+6/29); SCLC?